Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies.
<h4>Background</h4>Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infect...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-11-01
|
| Series: | PLoS Medicine |
| Online Access: | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004107&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850134360845451264 |
|---|---|
| author | Isabel Bergeri Mairead G Whelan Harriet Ware Lorenzo Subissi Anthony Nardone Hannah C Lewis Zihan Li Xiaomeng Ma Marta Valenciano Brianna Cheng Lubna Al Ariqi Arash Rashidian Joseph Okeibunor Tasnim Azim Pushpa Wijesinghe Linh-Vi Le Aisling Vaughan Richard Pebody Andrea Vicari Tingting Yan Mercedes Yanes-Lane Christian Cao David A Clifton Matthew P Cheng Jesse Papenburg David Buckeridge Niklas Bobrovitz Rahul K Arora Maria D Van Kerkhove Unity Studies Collaborator Group |
| author_facet | Isabel Bergeri Mairead G Whelan Harriet Ware Lorenzo Subissi Anthony Nardone Hannah C Lewis Zihan Li Xiaomeng Ma Marta Valenciano Brianna Cheng Lubna Al Ariqi Arash Rashidian Joseph Okeibunor Tasnim Azim Pushpa Wijesinghe Linh-Vi Le Aisling Vaughan Richard Pebody Andrea Vicari Tingting Yan Mercedes Yanes-Lane Christian Cao David A Clifton Matthew P Cheng Jesse Papenburg David Buckeridge Niklas Bobrovitz Rahul K Arora Maria D Van Kerkhove Unity Studies Collaborator Group |
| author_sort | Isabel Bergeri |
| collection | DOAJ |
| description | <h4>Background</h4>Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in the World Health Organization's Unity protocol (WHO Unity) for general population seroepidemiological studies, to estimate the extent of population infection and seropositivity to the virus 2 years into the pandemic.<h4>Methods and findings</h4>We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between January 1, 2020 and May 20, 2022. The review protocol is registered with PROSPERO (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies-those aligned with the WHO Unity protocol-were extracted and critically appraised in duplicate, with risk of bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate underascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% low- and middle-income countries [LMICs]) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/subnational scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6 to 28.8] to 86.7% [84.6% to 88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3% to 11.0%] in June 2020 to 95.9% [92.6% to 97.8%] in December 2021, in European high-income countries [HICs]). After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0 to 9 years and adults 60+ were at lower risk of seropositivity than adults 20 to 29 (p < 0.001 and p = 0.005, respectively). In a multivariable model using prevaccination data, stringent public health and social measures were associated with lower seroprevalence (p = 0.02). The main limitations of our methodology include that some estimates were driven by certain countries or populations being overrepresented.<h4>Conclusions</h4>In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions. |
| format | Article |
| id | doaj-art-700cc5e3567f4728a7ac663e40c033e1 |
| institution | OA Journals |
| issn | 1549-1277 1549-1676 |
| language | English |
| publishDate | 2022-11-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Medicine |
| spelling | doaj-art-700cc5e3567f4728a7ac663e40c033e12025-08-20T02:31:44ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762022-11-011911e100410710.1371/journal.pmed.1004107Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies.Isabel BergeriMairead G WhelanHarriet WareLorenzo SubissiAnthony NardoneHannah C LewisZihan LiXiaomeng MaMarta ValencianoBrianna ChengLubna Al AriqiArash RashidianJoseph OkeibunorTasnim AzimPushpa WijesingheLinh-Vi LeAisling VaughanRichard PebodyAndrea VicariTingting YanMercedes Yanes-LaneChristian CaoDavid A CliftonMatthew P ChengJesse PapenburgDavid BuckeridgeNiklas BobrovitzRahul K AroraMaria D Van KerkhoveUnity Studies Collaborator Group<h4>Background</h4>Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in the World Health Organization's Unity protocol (WHO Unity) for general population seroepidemiological studies, to estimate the extent of population infection and seropositivity to the virus 2 years into the pandemic.<h4>Methods and findings</h4>We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between January 1, 2020 and May 20, 2022. The review protocol is registered with PROSPERO (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies-those aligned with the WHO Unity protocol-were extracted and critically appraised in duplicate, with risk of bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate underascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% low- and middle-income countries [LMICs]) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/subnational scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6 to 28.8] to 86.7% [84.6% to 88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3% to 11.0%] in June 2020 to 95.9% [92.6% to 97.8%] in December 2021, in European high-income countries [HICs]). After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0 to 9 years and adults 60+ were at lower risk of seropositivity than adults 20 to 29 (p < 0.001 and p = 0.005, respectively). In a multivariable model using prevaccination data, stringent public health and social measures were associated with lower seroprevalence (p = 0.02). The main limitations of our methodology include that some estimates were driven by certain countries or populations being overrepresented.<h4>Conclusions</h4>In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions.https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004107&type=printable |
| spellingShingle | Isabel Bergeri Mairead G Whelan Harriet Ware Lorenzo Subissi Anthony Nardone Hannah C Lewis Zihan Li Xiaomeng Ma Marta Valenciano Brianna Cheng Lubna Al Ariqi Arash Rashidian Joseph Okeibunor Tasnim Azim Pushpa Wijesinghe Linh-Vi Le Aisling Vaughan Richard Pebody Andrea Vicari Tingting Yan Mercedes Yanes-Lane Christian Cao David A Clifton Matthew P Cheng Jesse Papenburg David Buckeridge Niklas Bobrovitz Rahul K Arora Maria D Van Kerkhove Unity Studies Collaborator Group Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Medicine |
| title | Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. |
| title_full | Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. |
| title_fullStr | Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. |
| title_full_unstemmed | Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. |
| title_short | Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. |
| title_sort | global sars cov 2 seroprevalence from january 2020 to april 2022 a systematic review and meta analysis of standardized population based studies |
| url | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004107&type=printable |
| work_keys_str_mv | AT isabelbergeri globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT maireadgwhelan globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT harrietware globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT lorenzosubissi globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT anthonynardone globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT hannahclewis globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT zihanli globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT xiaomengma globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT martavalenciano globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT briannacheng globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT lubnaalariqi globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT arashrashidian globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT josephokeibunor globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT tasnimazim globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT pushpawijesinghe globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT linhvile globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT aislingvaughan globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT richardpebody globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT andreavicari globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT tingtingyan globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT mercedesyaneslane globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT christiancao globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT davidaclifton globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT matthewpcheng globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT jessepapenburg globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT davidbuckeridge globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT niklasbobrovitz globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT rahulkarora globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT mariadvankerkhove globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies AT unitystudiescollaboratorgroup globalsarscov2seroprevalencefromjanuary2020toapril2022asystematicreviewandmetaanalysisofstandardizedpopulationbasedstudies |